SOHO 2022 | Impact of antifungal prophylaxis in patients with AML treated with an HMA and venetoclax
Jacqueline Garcia
• 28 Sep 2022
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the impact of antifungal prophylaxis in patients with acute myeloid leukemia (AML) treated with venetoclax and a hypomethylating agent (HMA). Overall, the study showed that the addition of antifungal therapy did not impact treatment response and suggested that antifungal prophylaxis may be useful in specific territorial regions depending on the infection rate. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
